Glucagon-Like Peptide 1 Recruits Muscle Microvasculature and Improves Insulin’s Metabolic Action in the Presence of Insulin Resistance
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) acutely recruits muscle microvasculature, increases muscle delivery of insulin, and enhances muscle use of glucose, independent of its effect on insulin secretion. To examine whether GLP-1 modulates muscle microvascular and metabolic insulin responses in the setting of insulin resistance, we assessed muscle microvascular blood volume (MBV), flow velocity, and blood flow in control insulin-sensitive rats and rats made insulin-resistant acutely (systemic lipid infusion) or chronically (high-fat diet [HFD]) before and after a euglycemic-hyperinsulinemic clamp (3 mU/kg/min) with or without superimposed systemic GLP-1 infusion. Insulin significantly recruited muscle microvasculature and addition of GLP-1 further expanded muscle MBV and increased insulin-mediated glucose disposal. GLP-1 infusion potently recruited muscle microvasculature in the presence of either acute or chronic insulin resistance by increasing muscle MBV. This was associated with an increased muscle delivery of insulin and muscle interstitial oxygen saturation. Muscle insulin sensitivity was completely restored in the presence of systemic lipid infusion and significantly improved in rats fed an HFD. We conclude that GLP-1 infusion potently expands muscle microvascular surface area and improves insulin’s metabolic action in the insulin-resistant states. This may contribute to improved glycemic control seen in diabetic patients receiving incretin-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These include promoting muscle remodel, enhancing postprandial muscle protein synthesis, increasing muscle microvascular blood flow, and improving muscle insulin resistance through weight loss [55, 56].”
From Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis (2025) · cites this paper as [56]
In the citing paper
“Since GLP-1Rs are absent in human skeletal muscle, effects must be indirect.”
From Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis (2025) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Glucagon-like peptide 1 (GLP-1), an incretin secreted in response to nutrient intake, stimulates glucosedependent insulin secretion, inhibits glucagon secretion and regulates postprandial glycemia (16,17).”
BackgroundYu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311 · cited 1×
“5 h after systemic lipid infusion (8,33), but extension of lipid infusion to 5 h significantly increases myocytic diacylglycerol concentration and protein kinase Cu activation and reduces insulin-mediated insulin receptor substrate-1 tyrosine phosphorylation and insulin receptor substrate-1–associated PI3-kinase activ…”
BackgroundDeFronzo, R. A., Gunnarsson, R., Björkman, O., Olsson, M., & Wahren, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111938 · Cited by 1,167 · cited 1×
“Skeletal muscle is a major target organ of insulin action and responsible for;80–90% of insulin-stimulated whole-body glucose disposal (1,2).”
BackgroundYe, J., Gao, Z., Yin, J., & He, Q. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00435.2007 · Cited by 840 · cited 1×
“Indeed, recent studies have shown that tissue hypoxia may contribute to the pathogenesis of insulin resistance likely via increased tissue inflammation (45).”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 2×
“These likely resulted from a direct action of GLP-1 on the endothelium as GLP-1 receptors are abundantly expressed on the vascular endothelium (21), and studies using rat arterial rings have shown a direct, dose-dependent vasorelaxant effect of GLP-1 that was abolished by the removal of the endothelium (22).”
BackgroundThe role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614 · cited 1×
“Glucagon-like peptide 1 (GLP-1), an incretin secreted in response to nutrient intake, stimulates glucosedependent insulin secretion, inhibits glucagon secretion and regulates postprandial glycemia (16,17).”
BackgroundCardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530 · cited 1×
“GLP-1 also has many nonpancreatic actions, including a beneficial effect on the endothelium (18).”
BackgroundNikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C., Shen, Y.-T., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 514 · cited 3×
“To examine whether GLP-1-mediated microvascular recruitment modulates insulin’s metabolic actions, we raised plasma insulin (3 mU/kg/min euglycemic insulin clamp) for 120 min after determining baseline MAP and collecting baseline samples for glucose and insulin levels at 0 min with or without a superimposed systemic i…”
BackgroundMethodKubota, T., Kubota, N., Kumagai, H., Yamaguchi, S., Kozono, H., Takahashi, T., Inoue, M., Itoh, S., Takamoto, I., Sasako, T., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.018 · Cited by 435 · cited 1×
“Recent evidence has confirmed a pivotal role of muscle microvasculature in the determination of muscle insulin action, as it provides the endothelial exchange surface area and changes in muscle microvascular perfusion profoundly affect insulin delivery to and action in muscle (5,6).”
Background
Cited by
Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function
Frampton, J., Murphy, K. G., Frost, G., & Chambers, E. S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0188-7 · Cited by 516
van Deuren, T., Blaak, E. E., & Canfora, E. E. (2022) · Obesity Reviews · doi:10.1111/obr.13498 · Cited by 181
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 155
Horiuchi, H., Kamikado, K., Aoki, R., Suganuma, N., Nishijima, T., Nakatani, A., & Kimura, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-60984-6 · Cited by 115
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
Horton, W. B., Love, K. M., Gregory, J. M., Liu, Z., & Barrett, E. J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00826.2024 · Cited by 106
Self-citationHepatic functions of GLP-1 and its based drugs: current disputes and perspectives
Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 83
Oxidative Stress, Intrauterine Growth Restriction, and Developmental Programming of Type 2 Diabetes
Rashid, C. S., Bansal, A., & Simmons, R. A. (2018) · Physiology · doi:10.1152/physiol.00023.2018 · Cited by 90
“Notwithstanding, multiple studies have shown that GLP-1R agonists improve mitochondria dysfunction (19, 20), ameliorate oxidative stress (19, 88), and enhance insulin sensitivity in skeletal muscle (1, 162) and liver (1, 39, 92) in human (27, 88) and animal models of T2D (17, 18, 147).”
BackgroundZhong, T., Tang, R., Gong, S., Li, J., Li, X., & Zhou, Z. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3207 · Cited by 90
Scalzo, R. L., Moreau, K. L., Ozemek, C., Herlache, L., McMillin, S., Gilligan, S., Huebschmann, A. G., Bauer, T. A., Dorosz, J., Reusch, J. E. B., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.003 · Cited by 72
“It is well established that GLP-1 improves blood flow to skeletal muscle via increases in endothelial and cardiac function in T2DM (Ceriello et al., 2006; Mafong & Henry, 2009; Chai et al., 2014).”
BackgroundResultInfluentialSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
Wang, N., Tan, A. W. K., Jahn, L. A., Hartline, L., Patrie, J. T., Lin, S., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Diabetes Care · doi:10.2337/dc19-1465 · Cited by 73
“Insulin-mediated muscle microvascular recruitment is reduced or abolished in rats that receive lipid infusion (10), are obese (11), or are fed a high-fat diet (HFD) (6,12).”
BackgroundSelf-citationVascular function, insulin action, and exercise: an intricate interplay
Zheng, C., & Liu, Z. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.02.002 · Cited by 71
Self-citationVascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
Inflammation-induced microvascular insulin resistance is an early event in diet-induced obesity
Zhao, L., Fu, Z., Wu, J., Aylor, K. W., Barrett, E. J., Cao, W., & Liu, Z. (2015) · Clinical Science · doi:10.1042/cs20150143 · Cited by 63
Self-citationDiabetes pathogenesis and management: the endothelium comes of age
Love, K. M., Barrett, E. J., Malin, S. K., Reusch, J. E. B., Regensteiner, J. G., & Liu, Z. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab024 · Cited by 57
“We have shown that GLP-1 infusion vasodilates conduit arteries and increases muscle microvascular perfusion in healthy (Chai et al., 2012) and insulin-resistant (Chai et al., 2014) rats, likely through a protein kinase A–NO-mediated pathway (Chai et al., 2012; Dong et al., 2013).”
BackgroundSelf-citationThe emerging role of sorting nexins in cardiovascular diseases
Yang, J., Villar, V. A. M., Rozyyev, S., Jose, P. A., & Zeng, C. (2019) · Clinical Science · doi:10.1042/cs20190034 · Cited by 55
Fu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 50
Self-citationChai, W., Fu, Z., Aylor, K. W., Barrett, E. J., & Liu, Z. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00205.2016 · Cited by 51
Self-citationMuscle Insulin Resistance and the Inflamed Microvasculature: Fire from Within
Liu, J., & Liu, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030562 · Cited by 50
“The importance of muscle microcirculation in the regulation of insulin’s metabolic actions is further strengthened by many observations in both humans and laboratory animals that multiple factors with proven evidence to affect muscle insulin action and glucose metabolism are able to induce muscle microvasculature recr…”
BackgroundSelf-citationSmits, M. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Diamant, M., van Raalte, D. H., & Serné, E. H. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305447 · Cited by 44
“For instance, increased microvascular perfusion in muscle could lead to increased glucose uptake, a beneficial phenomenon which was shown in rodents and dogs.(3,29) In our study, we observed insulin-independent reductions in glucose levels after exenatide infusion, which could be explained by increased muscle glucose…”
BackgroundGLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
“use of glucose [4] and may be indirectly mediated by the”
BackgroundLove, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40
“This increase in muscle microvascular perfusion after GLP-1 administration is associated with a robust increase in muscle insulin action and muscle interstitial oxygenation.(72) Although we previously observed that systemic GLP-1 infusion at pharmacological concentrations increases both muscle microvascular perfusion…”
BackgroundSelf-citationAdiponectin and insulin cross talk: The microvascular connection
Zhao, L., Fu, Z., & Liu, Z. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.08.001 · Cited by 38
“[54] Chai W, Zhang X, Barrett EJ, Liu Z.”
BackgroundSelf-citationZhai, R., Xu, H., Hu, F., Wu, J., Kong, X., & Sun, X. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15059 · Cited by 40
Wang, G., Zhu, G., Chen, C., Zheng, Y., Ma, F., Zhao, J., Lee, Y.-K., Zhang, H., & Chen, W. (2021) · Beneficial Microbes · doi:10.3920/bm2020.0148 · Cited by 38
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., Serné, E. H., & van Raalte, D. H. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307930 · Cited by 32
Liu, J., Aylor, K. W., & Liu, Z. (2023) · Diabetes · doi:10.2337/db22-0745 · Cited by 30
Self-citationHe, J., Ma, X., Li, W., Liu, Y., & Lin, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107192 · Cited by 30
The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis
Wang, H., Wang, L., Li, Y., Luo, S., Ye, J., Lu, Z., Li, X., & Lu, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111778 · Cited by 30
Liu, J., Aylor, K. W., Chai, W., Barrett, E. J., & Liu, Z. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00240.2021 · Cited by 30
Self-citationSjøberg, K. A., Rattigan, S., Jeppesen, J. F., Lundsgaard, A., Holst, J. J., & Kiens, B. (2015) · The Journal of Physiology · doi:10.1113/jp270129 · Cited by 27
“…was being prepared for publication, Chai et al. published that GLP-1 infusion in rats increased microvascular perfusion and was able to overcome acute lipid-induced insulin resistance of glucose disposal whereas the effect of GLP-1 was much smaller after the 4 week high fat diet (Chai et al. 2014).”
BackgroundEffect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
Yamada, S., Ogura, Y., Inoue, K., Tanabe, J., Sugaya, T., Ohata, K., Nagai, Y., Natsuki, Y., Hoshino, S., Watanabe, S., et al. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111472 · Cited by 25
Tan, A. W. K., Subaran, S. C., Sauder, M. A., Chai, W., Jahn, L. A., Fowler, D. E., Patrie, J. T., Aylor, K. W., Basu, A., & Liu, Z. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2017-00446 · Cited by 24
Self-citationBerberine improves intralipid-induced insulin resistance in murine
Dong, Z.-H., Lin, H., Chen, F., Che, X.-Q., Bi, W., Shi, S., Wang, J., Gao, L., He, Z., & Zhao, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0493-4 · Cited by 25
“The time course and steady-state whole-body glucose infusion rate (GIR) were calculated [29, 30].”
MethodRoberts‐Thomson, K. M., Parker, L., Betik, A. C., Wadley, G. D., Gatta, P. A. D., Marwick, T. H., & Keske, M. A. (2022) · The Journal of Physiology · doi:10.1113/jp282428 · Cited by 22
“GLP-1 infusion has been demonstrated to increase microvascular perfusion in the skeletal muscle of animals (Sjøberg et al. 2013; Chai et al. 2014) and humans (Sjøberg et al.”
van Deuren, T., Smolders, L., Hartog, A., Bouwman, F. G., Holst, J. J., Venema, K., Blaak, E. E., & Canfora, E. E. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1066950 · Cited by 25
Chai, W., Aylor, K. W., Liu, Z., Gan, L., Michaëlsson, E., & Barrett, E. J. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00203.2019 · Cited by 22
“Skeletal muscle phosphorylated and total protein kinase B (PKB or Akt), extracellular signal regulated protein kinase 1 and 2 (ERK1/2) and aortic endothelial nitric oxide synthase (eNOS) were measured using Western blot analysis, as previously described (4).”
MethodSelf-citationOnuma, H., Inukai, K., Kitahara, A., Moriya, R., Nishida, S., Tanaka, T., Katsuta, H., Takahashi, K., Sumitani, Y., Hosaka, T., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.136 · Cited by 21
Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
Lunder, M., Janić, M., & Šabović, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062796 · Cited by 20
“After infusion of the GLP-1 receptor agonist an improvement of microvascular blood volume and microvascular blood flow was observed in rats, the effect was associated with an increase in circulating NO levels [68].”
BackgroundSato, H., Kubota, N., Kubota, T., Takamoto, I., Iwayama, K., Tokuyama, K., Moroi, M., Sugi, K., Nakaya, K., Goto, M., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4071-8 · Cited by 19
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 21
Self-citationIncretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue
Xian, Y., Chen, Z., Deng, H., Cai, M., Liang, H., Xu, W., Weng, J., & Xu, F. L. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0639 · Cited by 18
Scalzo, R. L., Knaub, L. A., Hull, S., Keller, A. C., Hunter, K. S., Walker, L. A., & Reusch, J. E. B. (2018) · Physiological Reports · doi:10.14814/phy2.13754 · Cited by 17
“The impact of GLP-1 on vascular function in static conditions (independent of an exercise intervention) was previously appreciated (Nystr€om 2008; Mafong and Henry 2009; Chai et al. 2014; Keller et al. 2015; Scalzo et al. 2017).”
BackgroundExenatide induces autophagy and prevents the cell regrowth in HepG2 cells
Krause, G. C., Lima, K. G., Levorse, V. G. S., Haute, G. V., Gassen, R. B., Garcia, M. C. R., Pedrazza, L., Donadio, M. V. F., Luft, C., & de Oliveira, J. R. (2019) · EXCLI journal · doi:10.17179/excli2019-1415 · Cited by 20
“Studies have shown its beneficial effects in some diseases, including decreased appetite and gastric emptying, immune regulation, and neuronal protection (Abu-Hamdah et al., 2009; Chai et al., 2014; Seufert and Gallwitz, 2014; Ussher and Drucker, 2014).”
BackgroundJahn, L. A., Logan, B. R., Love, K. M., Horton, W. B., Eichner, N. Z. M., Hartline, L. M., WELTMAN, A. L., & Barrett, E. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00267.2021 · Cited by 15
Self-citationNerup, N. A., Ambrus, R., Lindhe, J., Achiam, M. P., Jeppesen, P. B., & Svendsen, L. B. (2017) · Microcirculation · doi:10.1111/micc.12367 · Cited by 13
Scalzo, R. L., Rafferty, D., Schauer, I. E., Huebschmann, A. G., Cree‐Green, M., Reusch, J. E. B., & Regensteiner, J. G. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.002 · Cited by 12
Voldstedlund, C. T., Sjøberg, K. A., Schlabs, F. L., Sigvardsen, C. M., Andersen, N. R., Holst, J. J., Hartmann, B., Wojtaszewski, J. F. P., Kiens, B., McConell, G. K., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06148-x · Cited by 10
“3a) and has been shown to increase microvascular perfusion in human and rodent muscle independently of insulin [38, 39].”
BackgroundCrossTalk proposal: De novo capillary recruitment in healthy muscle is necessary
Barrett, E. J., Keske, M. A., Rattigan, S., & Eringa, E. C. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.282137 · Cited by 9
“2010) activates AMP-kinase, Glucagon-like peptide-1 (Chai et al. 2014) acts”
Self-citationWang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01877-4 · Cited by 8
“These include promoting muscle remodel, enhancing postprandial muscle protein synthesis, increasing muscle microvascular blood flow, and improving muscle insulin resistance through weight loss [55, 56].”
Insulin-mediated muscle microvascular perfusion and its phenotypic predictors in humans
Love, K. M., Jahn, L. A., Hartline, L. M., Patrie, J. T., Barrett, E. J., & Liu, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-90935-8 · Cited by 8
Self-citationKatsanos, C. S., Liu, Z., & Atherton, P. J. (2026) · Comprehensive physiology · doi:10.1002/cph4.70126 · Cited by 8
“These effects of elevated plasma GLP-1 on muscle microvasculature are evident even in rodent models of insulin resistance induced by a high-fat diet (Chai et al. 2014).”
Self-citationHagve, M., Gjessing, P. F., Hole, M. J., Jansen, K. M., Fuskevåg, O., Mollnes, T. E., Larsen, T. S., & Irtun, Ø. (2019) · Endocrinology · doi:10.1210/en.2019-00374 · Cited by 7
Incretins in the Therapy of Diabetic Kidney Disease
Przezak, A., Bielka, W., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212312 · Cited by 7
“GLP1 ameliorates cardiac output and promotes vasodilatation in adipose tissue and skeletal muscle, increasing insulinstimulated glucose uptake in muscle [27,28].”
Effects of tetramethylpyrazine phosphate on pancreatic islet microcirculation in SD rats
Xu, X., Wu, L., Lu, Z., Xia, P., Zhu, X., & Gao, X. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0748-1 · Cited by 6
Hypertension Remission After Bariatric Surgery: Metrics, Mechanisms, and Patient Selection
Shirmohamadi, E., Ghasemloo, N., Ramezanpour, M. R., & Mohammadzadeh, N. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02280-1 · Cited by 6
GLP-1-derived therapies and risk of sarcopenia: myth or reality?
Scheen, A. J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2640980 · Cited by 5
Diabetes Pharmacotherapy and its effects on the Skeletal Muscle Energy Metabolism
Yu, B., Wang, D., Zhou, J., Huang, R., Cai, T., Hu, Y., Zhou, Y., & Ma, J. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575299439240216081711 · Cited by 5
Park, B. G., Kim, G. M., Lee, H., Ryu, J. H., Kim, D., Seong, J. Y., Kim, S., Park, Z., Kim, Y., Lee, J., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14546 · Cited by 4
Peart, L. A., Draper, M., & Tarasov, A. I. (2024) · Peptides · doi:10.1016/j.peptides.2024.171243 · Cited by 5
Yoo, S., Yang, E.-J., Lee, S. A., & Koh, G. (2017) · Endocrine Research · doi:10.1080/07435800.2017.1379023 · Cited by 3
“Then, how is GLP-1 linked to metabolic syndrome? Some studies have reported that GLP-1 infusion improves insulin resistance independently of its effect on insulin secretion in rats (19) and impaired incretin response after a mixed meal is associated with insulin resistance in healthy people (20).”
BackgroundImpact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Oliveira-Gomes, D. D., Pingili, A., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001225 · Cited by 2
“In addition, GLP-1 infusions have demonstrated enhanced muscle micro-vasculaturerecruitment, increased insulin deliveryto muscles, and improved glucose utilization independently of insulin secretion [22].”
The Skeletal Muscle Microvasculature and Its Effects on Metabolism
Kolka, C. M. (2016) · InTech eBooks · doi:10.5772/63535 · Cited by 3
Cellular Basis of Insulin Resistance: A Tale of the Microvasculature
Liu, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819801-8.00015-6 · Cited by 2
Self-citationExercise and the Brain–Gut Axis
Godinho, D. B., Fighera, M. R., & Royes, L. F. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99971-7.00019-9 · Cited by 1
Avogaro, A. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70184 · Cited by 2
“45 However, unlike insulin, GLP-1 The hemodynamic cooperation between GLP-1 and insulin in sustaining muscle perfusion and substrate oxidation: NO, Nitric oxide. retains its vascular efficacy in insulin-resistant conditions.”
Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk
Inia, J. A., Droog, S., Snabel, J. M., Menke, A. L., Caspers, M. P. M., de Jong, J. C. B. C., Jukema, J. W., Princen, H. M. G., & van den Hoek, A. M. (2026) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.1060 · Cited by 1
“GLP-1 can acutely improve hepatic and muscle insulin sensitivity and reduce endogenous glucose production [19-21], and can enhance insulin action via microvascular recruitment in muscle [22].”
Rebuttal from Eugene J. Barrett, Michelle A. Keske, Stephen Rattigan and Etto C. Eringa
Barrett, E. J., Keske, M. A., Rattigan, S., & Eringa, E. C. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.284604 · Cited by 1
“2013), Glucagon-like peptide-1 (Chai et al. 2014) and angiotensin II (Chai et al.”
BackgroundMethodSelf-citationLe GLP-1 au secours de la microvascularisation musculaire
A., F. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70872-7
Tan, A. W. K., Jahn, L. A., Hartline, L. M., Aylor, K. W., & Liu, Z. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00267.2025
Self-citationLipopolysaccharides et glucagon-like peptide 1 : des mécanismes moléculaires à la physiopathologie
Lebrun, L. (2016) · theses.fr (ABES) · doi:10.70675/2a6e27b7zd640z4026z814fzdc6a27d73fed
Transient Effects of Exenatide on Intraocular Pressure in a Rat Bone Defect Model
Özcan, C., Dellalbaşı, A. B., Doğan, E., Uğur, F., & Taşkın, R. (2026) · Dicle Üniversitesi Veteriner Fakültesi Dergisi · doi:10.47027/duvetfd.1858619
GIP Acutely Blunts Insulin- and GLP-1–Induced Muscle Microvascular Perfusion
Liu, J., Chun, C., Sin, T. K., Zhao, F., Aylor, K. W., Tushi, N. J., Sun, S., & Liu, Z. (2026) · Diabetes · doi:10.2337/db25-1009
Self-citationPan-hypoileism: an endocrine disease
Santoro, S. (2026) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2026rw2548
“(41,42) Although elevated GLP-1 levels associated with these surgeries are known to enhance insulin sensitivity, (43,44) the magnitude and rapidity of this improvement suggest that additional mechanisms remain to be elucidated.”
Metadata
- Authors
- Chai, W., Zhang, X., Barrett, E. J., & Liu, Z.
- Affiliations
- University of Virginia Health System (US)
- Central South University (CN)
- Corresponding author
- Liu, Zhenqi
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-07-17
- Volume
- 63
- Issue
- 8
- Pages
- 2788-2799
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC4113068
- OpenAlex
- W2129639460
- Cited by
- 73
- References
- 46
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 4 · 2017: 3 · 2016: 7 · 2015: 5 · 2014: 6
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL094722)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- glucagon-like peptide-1, insulin resistance, skeletal muscle microvasculature, muscle blood volume, insulin delivery, glucose disposal, insulin sensitivity, lipid infusion, high-fat diet, hyperinsulinemic-euglycemic clamp, muscle oxygen saturation, incretin-based therapy, glycemic control
- MeSH terms
- Animals, Glucose, Insulin, Insulin Resistance, Lipids, Male, Rats, Sprague-Dawley, Muscle, Skeletal, Neovascularization, Physiologic, Rats, Glucagon-Like Peptide 1, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.